Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3259-3271

  Santo, Loredana ^a,b   Hideshima, Teru ^b   Cirstea, Diana ^b   Bandi, Madhavi ^b   Nelson, Erik A ^b   Gorgun, Gullu ^b   Rodig, Scott ^c   Vallet, Sonia ^a,b   Pozzi, Samantha ^a,b   Patel, Kishan ^b   Unitt, Christine ^c   Squires, Matt ^d   Hu, Yiguo ^b   Chauhan, Dharminder ^b   Mahindra, Anuj ^a   Munshi, Nikhil C ^b   Anderson, Kenneth C ^b   Raje, Noopur ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; AURORA A KINASE; AURORA B KINASE; CASPASE 8; CASPASE 9; CELL DNA; HISTONE H3; INTERLEUKIN 6; JANUS KINASE 2; JANUS KINASE 3; LENALIDOMIDE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BONE MARROW STROMAL CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DNA SYNTHESIS INHIBITION; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, SCID; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; STAT3 TRANSCRIPTION FACTOR; THALIDOMIDE; TREATMENT OUTCOME; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956014006     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3012     Document Type: Article

References (39)

1. Ikezoe T. Aurora kinases as an anti-cancer target. Cancer Lett 2008;262:1-9.
2. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36. (Pubitemid 39626216)
3. Anand S, Penrhyn-Lowe S, Venkitaraman AR. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3:51-62. (Pubitemid 37443890)
4. Hirota T, Lipp JJ, Toh BH, Peters JM. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 2005;438:1176-80. (Pubitemid 41831689)
5. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active smallmolecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104:4106-11. (Pubitemid 47181586)
6. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. AZD1152, a novel and selective Aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-40. (Pubitemid 47443920)
7. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006;119:3664-75. (Pubitemid 44501870)
8. Cirstea D, Vallet S, Raje N. Future novel single agent and combination therapies. Cancer J 2009;15:511-18.
9. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of Aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009;113:4331-40.
10. Shi YJ, Reiman T, Li WQ, Maxwell CA, Sen S, Pilarski L, et al. Targeting Aurora kinases as therapy in multiple myeloma. Blood 2007;109:3915-21. (Pubitemid 46641744)
11. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from Aurora kinase inhibition. Blood 2008;111:1603-9. (Pubitemid 351213451)
12. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115:5202-13.
13. Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, et al. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 2009;147:672-6.
14. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20. (Pubitemid 37046923)
15. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18. (Pubitemid 38970551)
16. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008;112:5095-102.
17. Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, et al. AT9283, a potent inhibitor of the Aurora kinases and JAK2, has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010;150:46-57.
18. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J Med Chem 2009;52:379-88.
19. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of Aurora kinase inhibitors such as AT9283. Cell Cycle 2009;8:1921-9.
20. Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009;23:961-70.
21. Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C, et al. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008;49:559-69. (Pubitemid 351298342)
22. Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, et al. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 2009;20:2218-28.
23. Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Can Res 2006;12:4080-9. (Pubitemid 44078096)
24. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective smallmolecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7. (Pubitemid 38667616)
25. Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Exp Opin Ther Targets 2008;12:69-80. (Pubitemid 351247163)
26. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21. (Pubitemid 28018724)
27. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227-34. (Pubitemid 26428197)
28. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30. (Pubitemid 34627223)
29. Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54. (Pubitemid 37411723)
30. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Gen Dev 2004;14:29-36. (Pubitemid 38167474)
31. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the Auroras come into view. Curr Opin Cell Biol 2003;15:672-83. (Pubitemid 37487960)
32. Evans RP, Naber C, Steffler TS, Checkland T, Maxwell CA, Keats JJ, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140:295-302.
33. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Can Ther 2009;8:26-35.
34. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15. (Pubitemid 29077388)
35. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Can 2006;42:1564-73. (Pubitemid 44118771)
36. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Can Res 2006;66:7668-77. (Pubitemid 44289225)
37. Margolis RL, Lohez OD, Andreassen PR. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003;88:673-83. (Pubitemid 36258817)
38. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-80. (Pubitemid 36529846)
39. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Exp Rev Anticancer Ther 2006;6:1165-73. (Pubitemid 44304685)